AI assistant
Sending…
Niagen Bioscience, Inc. — Director's Dealing 2020
May 19, 2020
32418_dirs_2020-05-19_a70dd570-25d1-4bd0-8644-4b9ad8b0f588.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2020-05-19
Reporting Person: Fried Robert N (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-05-19 | Common Stock | P | 1000 | $4.69 | Acquired | 1393314 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 52001 | Indirect |
| Common Stock | 12746 | Indirect |
Footnotes
F1: 6,745 shares held by Jeremy Fried and 6,001 shares held by Benjamin Fried, who are sons of Robert Fried.
More from Niagen Bioscience, Inc.
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Mar 19
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24
Major Shareholding Notification
2026
Jan 30
Regulatory Filings
2025
Dec 22
Director's Dealing
2025
Nov 17
Regulatory Filings
2025
Nov 6